CN103012405A - New adenine type compound - Google Patents
New adenine type compound Download PDFInfo
- Publication number
- CN103012405A CN103012405A CN2013100193851A CN201310019385A CN103012405A CN 103012405 A CN103012405 A CN 103012405A CN 2013100193851 A CN2013100193851 A CN 2013100193851A CN 201310019385 A CN201310019385 A CN 201310019385A CN 103012405 A CN103012405 A CN 103012405A
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- ester
- oxalic
- obtains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FAVGGLZCNVDXNJ-ZCFIWIBFSA-N C[C@H](C[n]1c(ncnc2N)c2nc1)OCO Chemical compound C[C@H](C[n]1c(ncnc2N)c2nc1)OCO FAVGGLZCNVDXNJ-ZCFIWIBFSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed are a new adenine type compound (shown as formula I) and salt thereof, wherein the n= 1, 2 and 3. Experimentally proved, the new adenine type compound can suppress growth of cancer cells and used for preparing antineoplastic drugs. When the R1 is H, the new adenine type compound can generate ester with inorganic acid like phosphoric acid, nitric acid and sulfuric acid, and organic acid like formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, glycine, valine, maleic acid, fumaric acid, succinic acid and the like, can produce salt with acid or alkali group, and has good function of suppressing growth of the cancer cells.
Description
Technical field
The present invention relates to a kind of adenine compound with inhibition tumor cell growth.
Background technology
Tumour is the serious disease of harm humans health, and the preventing and controlling of tumour are the emphasis in medical research field always.At present, because the problems such as environmental pollution of bringing in the industrial development, human living environment quality constantly descends, and causes the sickness rate of tumor disease and lethality rate constantly to rise.Radiotherapy, chemotherapy are the Main Means for the treatment of at present tumour.But chemotherapy, radiotherapy have reduced immunity of organisms having suppressed also to have suppressed Normocellular growth when cancer cells is grown, and cause new complication.The specifics for the treatment of tumor disease can not be satisfactory, and clinical used cytotoxic drug selectivity is not high at present, causes Normocellular pernicious killing and wounding limited its application.Therefore, seek important directions new, become international field of medicaments without the antitumor drug of wound, acellular toxic action.
The present invention relates to a kind of new adenine compound, experimental results show that to have preferably activity through external, anti-tumor in vivo.
Disclosure of the Invention
The invention provides a kind of antineoplastic compound, is a kind of new adenine derivative and ester and salt, is specially formula (I) compound or its pharmacy acceptable salt:
n＝1，2，3。Wherein preferred: n=1,2.
The ester of above-claimed cpd and acid-respons gained, acid are selected from pharmaceutically acceptable mineral acid or organic acid, and wherein mineral acid is selected from nitric acid, sulfuric acid or phosphoric acid; Organic acid is selected from glycine, acetic acid, α-amino-isovaleric acid, formic acid, propionic acid, butyric acid, Succinic Acid, fumaric acid, Phenylsulfonic acid, methylsulfonic acid, phenylformic acid, toluylic acid, L-Ala, Methionin, arginine, Serine, phenylalanine, proline(Pro), tyrosine, aspartic acid, L-glutamic acid, Histidine, leucine, methionine(Met), Threonine, Pyrrolidonecarboxylic acid, tryptophane or α-amino-isovaleric acid, dextrocamphoric acid, oxysuccinic acid, citric acid, toxilic acid, succsinic acid, oxalic acid, pentanedioic acid, oxalic acid, lactic acid or propanedioic acid; Pamoic acid, hydroxynaphthoic acid, gentisinic acid, Whitfield's ointment, oxyacetic acid, amygdalic acid, lactic acid, 4-acetaminobenzoic acid or nicotinic acid.
Above-mentioned sour preferably phosphoric acid, acetic acid, glycine, α-amino-isovaleric acid, succsinic acid.
The ester that above-claimed cpd and acid-respons obtain again with the mineral acids such as sulfuric acid, phosphoric acid, sulfonic acid, hydrochloric acid, with glycine, L-Ala, Methionin, arginine, Serine, phenylalanine, proline(Pro), tyrosine, aspartic acid, L-glutamic acid, Histidine, leucine, methionine(Met), Threonine, Pyrrolidonecarboxylic acid, tryptophane or α-amino-isovaleric acid, dextrocamphoric acid, oxysuccinic acid, citric acid, toxilic acid, succsinic acid, oxalic acid, pentanedioic acid, oxalic acid, lactic acid or propanedioic acid; The organic acid reactions such as pamoic acid, hydroxynaphthoic acid, gentisinic acid, Whitfield's ointment, oxyacetic acid, amygdalic acid, lactic acid, 4-acetaminobenzoic acid or nicotinic acid obtain salt.
The ester that obtains when the reaction of above-claimed cpd and diprotic acid again with sodium, potassium, magnesium, Trometamol, diethanolamine, trolamine, glycine, Methionin or arginine reaction, can obtain salt.
The ester that above-claimed cpd and phosphoric acid, succsinic acid, fumaric acid, propanedioic acid, Succinic Acid, oxalic acid reaction obtain reacts with sodium, potassium, magnesium, Methionin, glycine, arginine, Trometamol, diethanolamine or trolamine, diethylamine, triethylamine again, obtains salt.
The half ester that above-claimed cpd and phosphoric acid, succsinic acid, fumaric acid, propanedioic acid, Succinic Acid, oxalic acid reaction obtain reacts resulting ester with the compound of alcoholic hydroxy again.
When n=1, we adopt following scheme to obtain a class novel compound, this novel compound as shown in the figure:
This compound can be obtained by following reaction scheme.
4,5 have respectively compound 4a, 4b, 4c, 4d, 4e and 5a, 5b, 5c, 5d and 5e among the figure.During for a, R
1=i-Pr; During for b, R
1=t-Bu; During for c, R
1=H.
When n=2, adopt following scheme to obtain a series of compounds, this novel compound as shown in the figure:
This series compound is to obtaining by following reaction scheme.
3,4 have respectively compound 3a, 3b, 3c and 4a, 4b, 4c among the figure.During for a, R
1=i-Pr; During for b, R
1=t-Bu; During for c, R
1=H.
Scheme during according to n=2 can obtain the series compound of n=3.
Compound 3,5,6,7 when n=1 in the scheme, 8 and when n=2 the compound in the scheme 2,4,5,6,7 through experimental results show that the effect with preferably inhibition tumor cell growth in antineoplastic external and body.
Specific embodiment:
During embodiment 1:n=1, the preparation of series compound:
(1), compound 2 is synthetic
Take by weighing 19.3 gram raw materials (compound 1) and be dissolved among the DCM of 60.0mL, open and stir.Ice-water bath is cooled to 0 ℃, slowly adds the diisopropyl ethyl amine of 25.8 grams.Temperature is no more than 5 ℃ of lower 9.7 gram MOMCl that slowly drip in the control reaction system, then reaction solution is risen to room temperature reaction 10h.Add the saturated ammonium chloride solution of 30.0mL, tell organic layer, the underpressure distillation desolventizing obtains the 21.4 thick products that digest compound 2 after the vacuum-drying, and productive rate is 90%, and crude product is not made purification process, is directly used in next step reaction.MS(m/z)：237.12。
(2), compound 3 is synthetic
The thick product compound 2 of 21.4 grams of previous step is dissolved among the DCM of 80.0mL, under 0 ℃, slowly splashes into 30mL boron trichloride dichloromethane solution (1.0M), finish, slowly rise to room temperature and continue to stir 1.5 hours.Add the saturated ammonium chloride solution of 20.0mL, separatory is got organic phase, and underpressure distillation desolventizing, vacuum-drying obtain the 18.7 thick products that digest compound 3, and productive rate is 93%, and crude product is not made purification process, is directly used in next step reaction.MS(m/z)：223.11。
(3), compound 4a/4b/4c's is synthetic
4.3g dissolve among the DMF that compound 3 is dissolved in the 20.0mL drying, add successively 5 gram N-Cbz-L-α-amino-isovaleric acids under the room temperature, 0.5 gram DMAP and 5 gram DCC in batches.Finish stirring at room reaction 12 hours.Filter, filtrate decompression concentrates desolventizing, and the silicagel column separation and purification gets 7.3g white solid (compound 4a), and productive rate is 83%.MS(m/z)：456.21。
Can obtain 6.6 with method and digest compound 4b, productive rate is 73%, MS (m/z): 470.52.
Can obtain 7.1 with method and digest compound 4c, productive rate is 89%, MS (m/z): 414.42.
(4), compound 5a/5b/5c's is synthetic
Accurately take by weighing 5.0 and digest compound 4a and be dissolved in the methyl alcohol of 25mL, add 0.5 gram, 10% Pd/C, H
2Pressure 5atm, stirring at room reaction 8h.Filter, filtrate concentrated the thick product of compound 5a, ethyl alcohol recrystallization obtains 2.8 and digests compound 5a, yield 78%.HNMR(400Hz，CDCl
3)：8.78(s，2H)，8.21(s，1H)，8.04(s，1H)，6.98(s，2H)，6.15(s，2H)，4.21(d，J＝8.4Hz，1H)，3.78(m，2H)，3.21(m，1H)，2.62(m，1H)，1.12(d，J＝4.2Hz，3H)，0.95(d，J＝8.4Hz，6H)；MS(m/z)：322.36。
Can obtain 2.7 with method and digest compound 5b, productive rate is 75%.HNMR(400Hz，CDCl
3)：8.84(s，2H)，8.13(s，1H)，8.01(s，1H)，6.91(s，2H)，6.16(s，2H)，3.74(m，2H)，3.41(s，1H)，3.12(m，1H)，1.14(d，J＝4.2Hz，3H)，0.94(s，9H)；MS(m/z)：336.39。
Can obtain 2.9 with method and digest compound 5c, productive rate is 86%.HNMR(400Hz，CDCl
3)：8.68(s，2H)，8.15(s，1H)，8.05(s，1H)，6.91(s，2H)，6.18(s，2H)，4.26(s，2H)，3.71(m，2H)，3.11(m，1H)，1.16(d，J＝8.4Hz，3H)；MS(m/z)：280.28。
(5), compound 6 is synthetic
Accurately take by weighing 5.0 and digest compound 3 and be dissolved among the THF of 25mL, the control temperature adds 0.9 gram NaH (60%) at 10～20 ℃ in batches, stirring at room reaction 0.5h.Then control temperature at 20 ℃ of THF solution (1.7 gram Acetyl Chloride 98Min.s are dissolved among the 10mLTHF) that drip Acetyl Chloride 98Min., dropwise stirring at room reaction 4h.Filter, filtrate concentrated the thick product of compound 6, the Virahol recrystallization obtains 4.9 and digests compound 6, yield 83%.HNMR(400Hz，CDCl
3)：8.23(s，1H)，8.05(s，1H)，6.97(s，2H)，6.11(s，2H)，3.75(m，2H)，3.11(m，1H)，2.19(s，3H)，1.16(d，J＝4.2Hz，3H)；MS(m/z)：265.12。
(6), compound 7 is synthetic
Digest compound 3,2.5 gram Succinic anhydrieds with 5.0, the DMAP of 0.1 gram and 3.0 gram triethylamines joined among the THF of 20mL, 60 ℃ of lower stirring reactions 12 hours.Stopped reaction, the cooling reaction solution is to room temperature, and the underpressure distillation desolventizing obtains dope, and the silicagel column separation and purification obtains 4.5 and digests compound 7, and productive rate is 63%.HNMR(400Hz，CDCl
3)：8.13(s，1H)，8.03(s，1H)，6.96(s，2H)，6.15(s，2H)，3.73(m，2H)，3.13(m，1H)，2.76(m，4H)，1.14(d，J＝4.2Hz，3H)；MS(m/z)：323.12。
Embodiment 2:n=2 time series compound adopts the preparation of figure below scheme:
3,4 have respectively compound 3a, 3b, 3c and 4a, 4b, 4c among the figure.During for a, R
1=i-Pr; During for b, R
1=t-Bu; During for c, R
1=H.
(1), compound 2 is synthetic
Take by weighing 19.3 gram raw materials (compound 1) and be dissolved among the 20.0mL THF, in the time of 0 ℃, it is slowly joined in the turbid solution of 4.8 gram NaH (60%), 20.0mL DMF and 60.0mL THF formation, finish, remove ice bath.After stirring 1h, add 27.5 gram benzyl acetate bromides, stirring at room 4h adds the 50.0mL saturated ammonium chloride solution, with 100.0mL dichloromethane extraction twice, merges organic layer, after dried over mgso, and vacuum concentration.Crude product is with the eluant solution of the normal hexane of 25% ethyl acetate, vacuum concentration elutriant.Product 20.0mL dissolve with ethanol after concentrated adds 6.8 gram sodium borohydrides under the room temperature, be heated to 40 ℃ of insulated and stirred 2h.Add the saturated ammonium chloride solution of 20.0mL, behind the stirring at room 15min, use 20.0mL dichloromethane extraction 3 times, merge organic layer, after the dried over mgso, behind the vacuum concentration, cross the post wash-out with 30-50%, obtain 17.6 after the vacuum-drying and digest compound 2, output is 74%.MS(m/z)：237.12。
(2), compound 3a/3b/3c's is synthetic
4.7g dissolve among the DMF that compound 3 is dissolved in the 20.0mL drying, add successively 5 gram N-Cbz-L-α-amino-isovaleric acids under the room temperature, 0.5 gram DMAP and 5 gram DCC in batches.Finish stirring at room reaction 12 hours.Filter, filtrate decompression concentrates desolventizing, and the silicagel column separation and purification gets 8.0g white solid (compound 3a), and productive rate is 85%.MS(m/z)：470.23。
Can obtain 7.4 with method and digest compound 3b, productive rate is 76%.MS(m/z)：484.24。
Can obtain 7.7 with method and digest compound 3c, productive rate is 90%.MS(m/z)：428.18。
(3), compound 4a/4b/4c's is synthetic
Accurately take by weighing 5.2 and digest compound 3a and be dissolved in the methyl alcohol of 25mL, add 0.5 gram, 10% Pd/C, H
2Pressure 5atm, stirring at room reaction 8h.Filter, filtrate concentrated the thick product of compound 4a, ethyl alcohol recrystallization obtains 3.0 and digests compound 4a, yield 81%.HNMR(400Hz，CDCl3)：8.84(s，2H)，8.19(s，1H)，8.06(s，1H)，6.91(s，2H)，4.31(m，2H)，3.86(d，J＝8.4Hz，2H)，3.53(m，2H)，3.24(m，1H)，2.89(m，1H)，2.65(m，1H)，1.14(d，J＝4.2Hz，3H)，0.98(d，J＝8.4Hz，6H)；MS(m/z)：336.19。
Can obtain 2.9 with method and digest compound 4b, productive rate is 78%.HNMR(400Hz，CDCl
3)：8.79(s，2H)，8.16(s，1H)，7.96(s，1H)，7.02(s，2H)，4.52(m，2H)，3.83(d，J＝8.4Hz，2H)，3.46(s，2H)，3.21(m，1H)，2.78(m，1H)，1.15(d，J＝4.2Hz，3H)，0.96(s，9H)；MS(m/z)：350.21。
Can obtain 3.1 with method and digest compound 4c, productive rate is 88%.HNMR(400Hz，CDCl
3)：8.71(s，2H)，8.16(s，1H)，8.01(s，1H)，6.93(s，2H)，4.46(m，2H)，3.95(d，J＝8.4Hz，2H)，3.82(m，2H)，3.56(m，2H)；2.95(m，1H)，1.23(d，J＝4.2Hz，3H)；MS(m/z)：294.14。
(4), compound 5 is synthetic
Accurately take by weighing 5.2 and digest compound 2 and be dissolved among the THF of 25mL, the control temperature adds 0.9 gram NaH (60%) at 10-20 ℃ in batches, stirring at room reaction 0.5h.Then control temperature at 20 ℃ of THF solution (2.1 gram Acetyl Chloride 98Min.s are dissolved among the 10mLTHF) that drip Acetyl Chloride 98Min., dropwise stirring at room reaction 4h.Filter, filtrate concentrated the thick product of compound 5, the Virahol recrystallization obtains 5.2 and digests compound 5, yield 85%.HNMR(400Hz，CDCl
3)：8.31(s，1H)，8.12(s，1H)，7.02(s，2H)，4.35(m，2H)，3.86(d，J＝8.4Hz，2H)，3.52(m，2H)，3.23(m，1H)，2.06(s，3H)，1.09(d，J＝4.2Hz，3H)；MS(m/z)：279.13。
(5), compound 6 is synthetic
Digest compound 2,2.5 gram Succinic anhydrieds with 5.2, the DMAP of 0.1 gram and 3.0 gram triethylamines joined among the THF of 20mL, 60 ℃ of lower stirring reactions 12 hours.Stopped reaction, the cooling reaction solution is to room temperature, and the underpressure distillation desolventizing obtains dope, and the silicagel column separation and purification obtains 4.8 and digests compound 6, and productive rate is 65%.HNMR(400Hz，CDCl
3)：8.21(s，1H)，8.05(s，1H)，7.03(s，2H)，4.42(m，2H)，3.93(d，J＝8.4Hz，2H)，3.52(m，2H)，2.96(m，1H)，2.68(m，4H)，1.19(d，J＝4.2Hz，3H)；MS(m/z)：337.14。
Embodiment 3: the anti-tumor activity of series compound
(1) external inhibition test (replacing compound 3 among the embodiment 1 with code name ZONK000 in the test)
Experiment material:
Medicine and reagent: ZONK001, white powder is provided by Guangdong Zonk Drug R ﹠ D Limited.
The RPMI1640 substratum: GIBCO company produces.
New-born calf serum (super), Hangzhou Sijiqing Biological Engineering Material Co., Ltd..
Trypsinase, Sigma company produces.
Cell strain: human hepatoma cell strain SMMC-7721, human lung adenocarcinoma cell line A549, human glioma cell line U251, Human gastric carcinoma cell line BGC-823 are all available from institute of Materia Medica,Chinese Academy of Medical Sciences pharmacological room.
Instrument: CO
2(Forma 3110 for incubator, USA), Bechtop (Ha Dong joins BCN-1360B), (Bio-Rad 550, USA) for microplate reader, inverted microscope (Nikon TE2000, Japan), Tissue Culture Flask (Costar, USA), 96 porocyte culture plates (Costar, USA).
Experimental technique:
The preparation of medicine and reagent: one bag of RPMI1640 substratum adds one liter in water, adds 2 gram sodium bicarbonates, and 100,000 unit penicillin and 100mg Streptomycin sulphate are regulated pH value to 7.4, with 0.22 μ m degerming membrane filtration degerming.The 95ml substratum adds deactivation new-born calf serum 5ml and is complete culture solution.Trypsinase is made into 0.25% solution with the D-hanks damping fluid, and 4 ℃ save backup after the filtration sterilization.
Accurately take by weighing ZONK001 100mg, be added in the 1.5ml centrifuge tube of sterilization, add DMSO 1ml, be made into 100mg/ml stoste ,-20 ℃ of freezing preservations.Get in right amount after melting before use and be diluted to the respective concentration application with complete culture solution.
Cell cultures and going down to posterity: the equal adherent culture of all cells is in containing 10ml complete culture solution Tissue Culture Flask, in 37 ℃, 5%CO
2, full closing under the humidity cultivate.Wash twice with sterilization D-hanks liquid after at the bottom of cell covers with bottle, add 0.25% trypsin digestion and cell 2 minutes, outwell trypsinase, after the jog cell can come off fully, add complete nutrient solution 30ml after, dispel cell with transfer pipet, be sub-packed in 3 new Tissue Culture Flasks, continue to cultivate.
Drug treating: get one bottle in the cell that just covered with, collecting cell behind the tryptic digestion with transfer pipet piping and druming evenly, is got two cell suspension Trypan Blues, in microscopically living cell counting number, adjusts cell number to 1 * 10 with complete culture solution
5Individual cells/ml.Every hole adds 100 μ l cell suspensions in 96 porocyte culture plates, and culture plate is placed CO
2Cultivated 12 hours in the incubator, in every hole, add the complete culture solution that 100 μ l contain different concns ZONK001 after taking out culture plate, so that the medicine final concentration is respectively 80.0,60.0,45.0,33.8 and 25.3 μ g/ml, each concentration is established 4 parallel holes, other establishes 4 porocytes and adds not the pastille complete culture solution and make negative control hole, 4 porocytes add the complete culture solution that contains vincristine(VCR) and make positive control, and the vincristine(VCR) final concentration is 5 μ g/ml.Add behind the medicine culture plate mixing that on the microwell plate vibrator, vibrates, place CO
2Continue in the incubator to cultivate 48 hours.Take out culture plate, every hole adds the MTT liquid of 10 μ l 5mg/ml, the vibration mixing, continue to cultivate 4 hours, discard original fluid, add DMSO 150 μ l in every hole, fully vibration is with the crystallization of dissolving bluish voilet, on Bio-Rad 550 microplate reader, measure the photoabsorption in each hole, measure wavelength 570nm, reference wavelength 630nm.
Calculate the inhibiting rate of medicine on cell proliferation according to each hole OD value:
Do straight-line regression according to the inhibiting rate that the logarithm of drug level is corresponding, obtain straight-line equation, calculate inhibiting rate corresponding drug level 50% time and be ZONK001 to the 503nhibiting concentration (IC of tumour cell
50).
Under above-mentioned similarity condition, measure the IC of every strain cell
50, the continuous triplicate of every strain cell experiment.
Experimental result:
Table 1 ZONK001 is to half 503nhibiting concentration (IC of different tumor cell lines
50, μ g/ml)
(2) inhibition test in the body
Experiment material:
Medicine and reagent: ZONK002 (compound 2 among the embodiment 2), white powder is provided by Guangdong Zonk Drug R ﹠ D Limited.
Cyclophosphamide for injection, Hengrui Medicine Co., Ltd., Jiangsu Prov.'s product.
Animal and knurl strain: SPF level Kunming kind small white mouse, body weight 18～22g is provided by Shandong Luye Pharmaceutical Co., Ltd.'s animal center, conformity certification number: SYXK (Shandong) 20030020.SPF level C57BL/6 inbred mouse, body weight 18～22g, available from Institute of Experimental Animals, Chinese Academy of Medical Sciences, conformity certification number: SCXK11-00-0006.Mouse H22 liver cancer, B16 melanoma are all drawn from institute of materia medica, Chinese Academy of Medical Sciences Beijing.
Instrument: CO
2Incubator (Forma 3110, USA), and Bechtop (BCN-1360, east, Harbin connection), inverted microscope (Nikon).
Experiment 1:H22 liver cancer
H22 liver cancer is got the ascites preservation of going down to posterity behind the Kunming mouse intraperitoneal inoculation.Get the H22 liver cancer tumor-bearing mice that ascites went down to posterity the 10th, take off cervical vertebra and put to death mouse, the sterilization skin of abdomen is drawn oyster white ascites with asepsis injector, adjusts tumour cell concentration as 1 * 107 cell/ml take injection physiological saline.With cotton ball soaked in alcohol sterilization Kunming mouse right side armpit skin, in the above-mentioned tumor cell suspension 0.2ml of subcutaneous vaccination, the conventional raising.
Grouping and administration: 50 of tumor-bearing mices, be divided at random 5 groups by body weight, 10 every group, be respectively model group, endoxan group, ZONK002 10,30, the 90mg/kg group.Each organizes mouse by dosage shown in the table 2 and mode administration, and the endoxan group only gives endoxan one time in the abdominal cavity in lotus knurl second day, and ZONK000 organizes equal every day of tail intravenously administrable 1 time, continuous 10 days.Administration volume 20ml/kg body weight.After the last administration 24 hours, take off cervical vertebra and put to death mouse, weigh, strip tumor tissue and weigh, calculate tumour inhibiting rate.
The result with
Expression is organized a significant difference relatively with the t check.
The result shows, the ZONK002 continuous intravenous injection of 30mg/kg 10 days is inhibited to the growth of mice transplanted tumor H22 liver cancer.
Table 2 ZONK002 is to the restraining effect of mouse H22 liver cancer growth
Compare with model group:
*, P＜0.05;
*, P＜0.01.
Experiment 2:B16 melanoma
The B16 melanoma is in the C57BL/6 mouse oxter subcutaneous vaccination preservation of going down to posterity.Select the B16 melanoma tumor-bearing mice that tumor growth is good, nothing is downright bad or go down to posterity and preserve in oxter liquefaction, take off cervical vertebra and put to death mouse, after the 75% alcohol-pickled sterilization, the aseptic tumor tissue of getting, the injection physiological saline that adds 5 times of volumes (W/V), grind to form homogenate with tissue homogenizer system, get tumor cell suspension with the 200 order stainless steel sift net filtrations of sterilizing.The same to be inoculated in the C57BL/6 mouse armpit subcutaneous, the conventional raising.
Grouping and administration: 50 of tumor-bearing mices, be divided at random 5 groups by body weight, 10 every group, be respectively model group, endoxan group, ZONK002 10,30, the 90mg/kg group.Each organizes mouse by dosage shown in the table 3 and mode administration, and the endoxan group only gives endoxan one time in the abdominal cavity in lotus knurl second day, and ZONK002 respectively organizes equal every day of tail intravenously administrable 1 time, continuous 10 days.Administration volume 20ml/kg body weight.After the last administration 24 hours, take off cervical vertebra and put to death mouse, weigh, strip tumor tissue and weigh, calculate tumour inhibiting rate.
The result with
Expression is organized a significant difference relatively with the t check.
The result shows, the ZONK002 group continuous intravenous injection of 30mg/kg 10 days is inhibited to the melanomatous growth of mice transplanted tumor B16.
Table 2 ZONK002 is to the restraining effect of mouse B16 melanoma growth
Compare with model group:
*, P＜0.05;
*, P＜0.01.
Embodiment 4: the research of series compound extracorporeal anti-tumor function
1. experiment material
1.1 medicine and reagent
Get four sample: ZONK003 (compound 5 among the embodiment 1), ZONK004 (compound 6 among the embodiment 1), ZONK005 (compound 5 among the embodiment 2) and ZONK006 (compound 6 among the embodiment 2) provide by Guangdong Zonk Drug R ﹠ D Limited.Used medicine takes by weighing 0.1g, adds DMSO 1ml, is made into 100mg/ml stoste, 4 ℃ of preservations.Get in right amount after melting before use and be diluted to the respective concentration application with complete culture solution.
DMEM nutrient solution (GIBCO, Invitrogen, U.S.A); Foetal calf serum (FBS; GIBCO, Invitrogen); 100U/ml of penicillin, and 100 μ g/ml of streptomycin (GIBCO, Grand Island, NY, USA); The blue MTT (thiazolyl blue, Sigma, MO, U.S.A.) of methylthiazol; Trypsin 0.25% Trypsin, GIBCO, Invitrogen); DMSO (100ml, sigma packing) is Beijing ancient cooking vessel Co., Ltd product; It is pure that all the other reagent are chemical analysis.
1.2 cell
The human cervical carcinoma Hela cell, the human hepatocellular carcinoma BEL-7402 cell, people's mucus epiderm-like lung cancer A549 cell, human breast carcinoma MCF-7/s cell, human glioma U251 cell, the normal embryonic kidney HEK-293 of people cell, all be purchased from U.S. American Type Culture Collection (ATCC), all tumour cells (contain 10%FBS with the DMEM substratum, 100U/ml of penicillin, and 100 μ g/ml of streptomycin), people's normal chick embryo nephrocyte RPMI1640 substratum (10%FBS, 100U/ml of penicillin, and100 μ g/ml of streptomycin) cultivates, go down to posterity, place 37 ℃, 5%CO
2Normally cultivate in the incubator.
2. laboratory apparatus
Microplate reader (U.S. Bio-Rad, Model550); Incubator (Thermo Forma, Incubator, USA); Versatile compact centrifuge (HITACHI, RX ser ies, Himac CF 16RX); Inverted microscope (leika TE2000, Japan), the adjustable liquid-transfering gun of Thermo; The single single face clean work station of SW-CJ-IFD type (Purifying Equipment Co., Ltd., Suzhou.NO:070587); Tissue Culture Flask (Costar, USA), 96 porocyte culture plates (Costar, USA), the Delta320 plum Teller-desk-top pH meter of Tuo benefit METTLER.
3. experimental technique
To be in logarithmic phase, adherent rate reaches 80% left and right sides cell in good condition and goes down to posterity.Abandon substratum, remove serum deprivation 1-2 time with the PBS flushing, add 1ml0.25%Trypsin-0.01%EDTA (hatching for 37 ℃) digestion 1-2min, add and contain FBS substratum termination digestion, the following centrifugal 2-3min of 800r/min abandons supernatant, and re-suspended cell is in the substratum of 10%FBS, and obtained cell suspension carries out cell counting, adjust density, with 1 * 10
5/ ml is inoculated in 96 orifice plates (100 μ l/well), and in 5%CO
237 ℃ of incubator overnight incubation.Add the ZONK078No of different concns, ZONK068T, ZONK058C and ZONK088CT medicine, 100 μ l/well (making its final concentration is 30,60,120,240,480 μ g/ml) next day in the cell; Establish simultaneously blank group (0 μ M), establish again 3 holes, continue to cultivate.Behind drug effect 48h, abandon substratum, every hole adds the PBS (PH7.2) that 100 μ l contain 0.5mg/ml MTT, after cultivating 4h, the quick turnover panel method of attached cell is removed substratum, every hole adds the DMSO of 100 μ l, trace shaker vibration 5min measures the OD value in the 490nm wavelength, and the experiment triplicate is averaged, calculate ZONK003, ZONK004, each concentration medicine of ZONK005 and ZONK006 is to the inhibiting rate (Inhibition Rate, IR%) of Proliferation of Tumor Cells In Vitro, calculate as follows each concentration medicine to the inhibiting rate (Inhibit ion Rate, IR%) of Proliferation of Tumor Cells In Vitro:
IR％＝(1-OD
sampale/OD
control)×100％
And with SPSS11.5 computed in software ZONK003, ZONK004, the half-inhibition concentration IC of ZONK005 and ZONK006
50
4. result
Above compound all has comparatively significant tumor killing effect, and experimental result sees the following form:
Claims (8)
1. suc as formula the compound of structure shown in (I):
Wherein: n=1,2,3; R
1=-H
2. the ester of compound as claimed in claim 1 and acid-respons gained, acid is selected from pharmaceutically acceptable mineral acid or organic acid, and wherein mineral acid is selected from nitric acid, sulfuric acid or phosphoric acid; Organic acid is selected from glycine, acetic acid, α-amino-isovaleric acid, formic acid, propionic acid, butyric acid, Succinic Acid, fumaric acid, Phenylsulfonic acid, methylsulfonic acid, phenylformic acid, toluylic acid, L-Ala, Methionin, arginine, Serine, phenylalanine, proline(Pro), tyrosine, aspartic acid, L-glutamic acid, Histidine, leucine, methionine(Met), Threonine, Pyrrolidonecarboxylic acid, tryptophane or α-amino-isovaleric acid, dextrocamphoric acid, oxysuccinic acid, citric acid, toxilic acid, succsinic acid, oxalic acid, pentanedioic acid, oxalic acid, lactic acid or propanedioic acid; Pamoic acid, hydroxynaphthoic acid, gentisinic acid, Whitfield's ointment, oxyacetic acid, amygdalic acid, lactic acid, 4-acetaminobenzoic acid or nicotinic acid.
3. ester according to claim 2, wherein:
4. described compound according to claim 1-3, with mineral acids such as sulfuric acid, phosphoric acid, sulfonic acid, hydrochloric acid, with glycine, L-Ala, Methionin, arginine, Serine, phenylalanine, proline(Pro), tyrosine, aspartic acid, L-glutamic acid, Histidine, leucine, methionine(Met), Threonine, Pyrrolidonecarboxylic acid, tryptophane or α-amino-isovaleric acid, dextrocamphoric acid, oxysuccinic acid, citric acid, toxilic acid, succsinic acid, oxalic acid, pentanedioic acid, oxalic acid, lactic acid or propanedioic acid; The salt that the organic acid reactions such as pamoic acid, hydroxynaphthoic acid, gentisinic acid, Whitfield's ointment, oxyacetic acid, amygdalic acid, lactic acid, 4-acetaminobenzoic acid or nicotinic acid obtain.
5. formula I compound and diprotic acid react the ester that obtains and react the salt that obtains with sodium, potassium, magnesium, Trometamol, diethanolamine, trolamine, glycine, Methionin or arginine again.
6. formula I compound and phosphoric acid, succsinic acid, fumaric acid, propanedioic acid, Succinic Acid, oxalic acid react the ester that obtains and react the salt that obtains with sodium, potassium, magnesium, Methionin, glycine, arginine, Trometamol, diethanolamine or trolamine, diethylamine, triethylamine again.
7. the half ester that obtains of formula I compound and phosphoric acid, succsinic acid, fumaric acid, propanedioic acid, Succinic Acid, oxalic acid reaction reacts resulting ester with the compound of alcoholic hydroxy again.
8. the purposes of the described compound of claim 1-7 in preparation medicine for treating tumor thing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100193851A CN103012405A (en) | 2013-01-17 | 2013-01-17 | New adenine type compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100193851A CN103012405A (en) | 2013-01-17 | 2013-01-17 | New adenine type compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103012405A true CN103012405A (en) | 2013-04-03 |
Family
ID=47961557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100193851A Pending CN103012405A (en) | 2013-01-17 | 2013-01-17 | New adenine type compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103012405A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106083856A (en) * | 2016-06-14 | 2016-11-09 | 河南师范大学 | A kind of purines alanine derivatives that can be used for oncotherapy and its preparation method and application |
| CN106074557A (en) * | 2016-06-14 | 2016-11-09 | 河南师范大学 | The application in preparing cancer therapy drug of the D type guanine alanine |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6028076A (en) * | 1996-07-03 | 2000-02-22 | Japan Energy Corporation | Purine derivative |
| CN101443021A (en) * | 2006-03-14 | 2009-05-27 | Alt解决方案公司 | Prevention and treatment of cancer and other diseases |
-
2013
- 2013-01-17 CN CN2013100193851A patent/CN103012405A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6028076A (en) * | 1996-07-03 | 2000-02-22 | Japan Energy Corporation | Purine derivative |
| CN101443021A (en) * | 2006-03-14 | 2009-05-27 | Alt解决方案公司 | Prevention and treatment of cancer and other diseases |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106083856A (en) * | 2016-06-14 | 2016-11-09 | 河南师范大学 | A kind of purines alanine derivatives that can be used for oncotherapy and its preparation method and application |
| CN106074557A (en) * | 2016-06-14 | 2016-11-09 | 河南师范大学 | The application in preparing cancer therapy drug of the D type guanine alanine |
| CN106074557B (en) * | 2016-06-14 | 2019-07-05 | 河南师范大学 | D type guanine alanine is preparing the application in medicines resistant to liver cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103804312B (en) | Aza cyclic cpds and its production and use | |
| CN103044395B (en) | Desloratadine-containing amino acid derivative as well as preparation method and application thereof | |
| CN102762554A (en) | (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors | |
| CN102702298A (en) | Glycyrrhetinic acid derivative and preparation method and medical application thereof | |
| CN103012405A (en) | New adenine type compound | |
| JP4779058B2 (en) | α-amino group-N-substituted amide compound, pharmaceutical composition containing the compound and use thereof | |
| CN103965299A (en) | Cyclic pentapeptide as well as synthetic method and application thereof | |
| CN102746212B (en) | Beta-elemene indole derivative, preparation and application thereof | |
| CN106074557A (en) | The application in preparing cancer therapy drug of the D type guanine alanine | |
| CN107698484B (en) | Preparation method and application of lenalidomide derivative | |
| CN102249982B (en) | Pleuromutilin compound, and medical composition, preparation method and application thereof | |
| CN101541717B (en) | A trans-cinnamic acid derivative, its preparation method and the use | |
| CN104151304B (en) | A kind of triazole class compounds | |
| CN107513089B (en) | Novel cytidine derivative dimer and application thereof | |
| CN103864765A (en) | Benzoazepine derivative containing five-membered heterocycle as well as preparation method and application of derivative | |
| CN102675311A (en) | Fluoro-acrylamide derivative | |
| JP2012512839A (en) | Antitumor compounds | |
| CN102212013A (en) | Polyamine compound and preparation method and application thereof | |
| CN113387864B (en) | S-indole benzamide derivative and preparation method and application thereof | |
| CN104193745B (en) | A kind of imidazopyrimidine carboxylic acid compound and preparation method thereof | |
| US20210206798A1 (en) | Betulastatin compounds | |
| CN112300245B (en) | RGDS and theanine co-modified 5-fluorouracil, and synthesis, activity and application thereof | |
| CN109824642B (en) | Chrysin phenylalanine derivative with anti-lung cancer activity | |
| CN112300244B (en) | 5-fluorouracil modified by theanine alone or together with RGDS, and synthesis, activity and application thereof | |
| CN104892546B (en) | One class (2H) 1,4 benzo thiazides compounds and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: REN JINHAI Free format text: FORMER OWNER: SU CHUNHUA Effective date: 20131104 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510630 GUANGZHOU, GUANGDONG PROVINCE TO: 050000 SHIJIAZHUANG, HEBEI PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20131104 Address after: 050000 Department of Hematology, Second Hospital, Hebei Medical University, 215 Heping West Road, Hebei, Shijiazhuang Applicant after: Ren Jinhai Address before: 510630 Guangdong city of Guangzhou province Tianhe District Zhonghaikangcheng Huayuan Road clove Street No. 2 Room 202 Applicant before: Su Chunhua |
|
| ASS | Succession or assignment of patent right |
Owner name: SU CHUNHUA Free format text: FORMER OWNER: REN JINHAI Effective date: 20140127 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 050000 SHIJIAZHUANG, HEBEI PROVINCE TO: 510630 GUANGZHOU, GUANGDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140127 Address after: 510630 Guangdong province Guangzhou Science City skim Springs Road No. 3, A District 1105 Applicant after: Su Chunhua Address before: 050000 Department of Hematology, Second Hospital, Hebei Medical University, 215 Heping West Road, Hebei, Shijiazhuang Applicant before: Ren Jinhai |
|
| ASS | Succession or assignment of patent right |
Owner name: GUANGDONG ZONK DRUG R + D LIMITED Free format text: FORMER OWNER: SU CHUNHUA Effective date: 20140905 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20140905 Address after: 510630 Guangdong province Guangzhou Science City skim Springs Road No. 3, A District 1105 Applicant after: Guangdong Zonk Drug R & D Limited Address before: 510630 Guangdong province Guangzhou Science City skim Springs Road No. 3, A District 1105 Applicant before: Su Chunhua |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130403 |